Aphranel

Shanghai Moyom Biotechnology (operating under its flagship brand Aphranel) is a Chinese medical aesthetics and biotechnology company specializing in the research, development, and manufacturing of advanced nano-medical biomaterials and absorbable Class III medical implants. The company's core product, the Aphranel MagiCCrystal Novo CaHA Filler, is a regenerative dermal filler composed of 30% calcium hydroxylapatite (CaHA) microspheres and 70% carboxymethyl cellulose (CMC) gel carrier. Utilizing patented ACD-MT™ microsphere and PCD-ETT™ gel technologies, the filler provides immediate structural support and stimulates progressive collagen regeneration. Aphranel is the first China-developed CaHA injectable to receive NMPA Class III medical device certification and has also achieved EU MDR certification, positioning the company for rapid global expansion in the medical aesthetics market.